ONCOLYTICS BIOTECH INC.

Analyst Reco. Oncolytics Biotech Inc. Nasdaq

Equities

ONCY

CA6823108759

Market Closed - Nasdaq Other stock markets 21:00:00 31/05/2024 BST			5-day change	1st Jan Change
1.07 ^USD	-0.93%		-1.83%	-20.74%

05-24	Oncolytics Biotech Inc. Presents Two Abstracts At the 2024 American Society of Clinical Oncology Annual Meeting	CI
05-24	Oncolytics Biotech Says ASCO Abstracts Highlight Pelareorep's Treatment Potential in Pancreatic Cancer	MT

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

RBC on Oncolytics Biotech's Upcoming Type C Meeting With FDA	05-13	MT
HC Wainwright Adjusts Price Target on Oncolytics Biotech to $5 From $15, Maintains Buy Rating	11-13	MT
Oncolytics Biotech Brief: Announcing Updated Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial that Show Pelareorep "Driving Robust Increases in Progression-Free Survival and Confirmed Overall Response Rate"	05/06/23	MT
Oncolytics Biotech Inc. Announces Updated Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial That Show Pelareorep Driving Robust Increases in Progression-Free Survival and Confirmed Overall Response Rate	05/06/23	CI
JonesTrading Initiates Oncolytics Biotech at Buy With $9 Price Target	24/05/23	MT
Canaccord Genuity Adjusts Price Target on Oncolytics Biotech to $5 From $6, Maintains Buy Rating	06/03/23	MT
Oncolytics Biotech Inc. Reports Interim Results from Phase 1/2 Goblet Study Showing A 70% Objective Response Rate in Pancreatic Cancer At the SITC Annual Meeting	07/11/22	CI
Oncolytics Biotech Brief: Reporting Interim Results from Phase 1/2 GOBLET Study Showing a 70% Objective Response Rate in Pancreatic Cancer at the SITC Annual Meeting	07/11/22	MT
Maxim Initiates Oncolytics Biotech With Buy Rating, Sets Price Target at $3	06/10/22	MT
RBC Capital Keeps OutperformSpeculative on Oncolytics Biotech	04/03/22	MT
ONCOLYTICS BIOTECH : RBC Capital Keeps Outperform/Speculative Risk Rating, $6 TP on Oncolytics Biotech	12/03/21	MT
ONCOLYTICS BIOTECH : HC Wainwright Starts Oncolytics Biotech at Buy With $15 Price Target	17/02/21	MT
ONCOLYTICS BIOTECH : RBC Capital Keeps Outperform/Speculative Risk on Oncolytics Biotech After Q3	13/11/20	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

As early as today, start finding the best investment opportunities!

Optimize my profits

fermer